Stock listing
KRX:084650 LabGenomics Co., Ltd. (랩지노믹스) 주가
Follow LabGenomics Co., Ltd. into a list and get an email when it puts out news.
Share price · KRX:084650
₩1,958.00 KRW +85.00 (+4.5%)
Close on Nov 20, 2026
- Day range
- ₩1,896.00 – ₩1,994.00 KRWNov 20, 2026
- Volume
- 26,479 sharesNov 20, 2026
- Market cap
- ₩17.77B KRWAt the close on Nov 20, 2026 · price × 9.08M shares outstanding
- 52-week range
- ₩1,500.00 – ₩11,375.00 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ₩265.4M KRWMedian day 55,311 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:084650 · KRW, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ₩1,958.00 | +85.00 | +4.5% | ₩1,896.00 | ₩1,994.00 | ₩1,896.00 | 26,479 | |
| ₩1,873.00 | +39.00 | +2.1% | ₩1,834.00 | ₩1,873.00 | ₩1,745.00 | 34,675 | |
| ₩1,834.00 | -30.00 | -1.6% | ₩1,864.00 | ₩1,915.00 | ₩1,710.00 | 29,859 | |
| ₩1,864.00 | -121.00 | -6.1% | ₩2,040.00 | ₩2,040.00 | ₩1,861.00 | 50,401 | |
| ₩1,985.00 | 0.00 | 0.0% | ₩1,972.00 | ₩2,015.00 | ₩1,972.00 | 40,526 | |
| ₩1,985.00 | -14.00 | -0.7% | ₩1,958.00 | ₩2,020.00 | ₩1,955.00 | 45,589 | |
| ₩1,999.00 | +99.00 | +5.2% | ₩1,900.00 | ₩2,030.00 | ₩1,900.00 | 56,490 | |
| ₩1,900.00 | +28.00 | +1.5% | ₩1,890.00 | ₩1,964.00 | ₩1,852.00 | 85,467 | |
| ₩1,872.00 | -22.00 | -1.2% | ₩1,885.00 | ₩1,903.00 | ₩1,815.00 | 42,699 | |
| ₩1,894.00 | -14.00 | -0.7% | ₩1,900.00 | ₩1,930.00 | ₩1,817.00 | 35,615 | |
| ₩1,908.00 | +88.00 | +4.8% | ₩1,838.00 | ₩1,930.00 | ₩1,824.00 | 66,697 | |
| ₩1,820.00 | +8.00 | +0.4% | ₩1,812.00 | ₩1,850.00 | ₩1,724.00 | 59,503 | |
| ₩1,812.00 | -93.00 | -4.9% | ₩1,905.00 | ₩1,905.00 | ₩1,799.00 | 57,617 | |
| ₩1,905.00 | -190.00 | -9.1% | ₩2,045.00 | ₩2,075.00 | ₩1,770.00 | 85,525 | |
| ₩2,095.00 | +85.00 | +4.2% | ₩2,010.00 | ₩2,095.00 | ₩1,913.00 | 46,256 | |
| ₩2,010.00 | -5.00 | -0.2% | ₩2,035.00 | ₩2,065.00 | ₩1,870.00 | 102,693 | |
| ₩2,015.00 | +165.00 | +8.9% | ₩1,851.00 | ₩2,055.00 | ₩1,851.00 | 138,170 | |
| ₩1,850.00 | +81.00 | +4.6% | ₩1,769.00 | ₩1,903.00 | ₩1,769.00 | 81,768 | |
| ₩1,769.00 | +69.00 | +4.1% | ₩1,785.00 | ₩1,801.00 | ₩1,666.00 | 167,696 | |
| ₩1,700.00 | +70.00 | +4.3% | ₩1,630.00 | ₩1,878.00 | ₩1,500.00 | 723,686 | |
| ₩1,630.00 | -665.00 | -29.0% | ₩2,305.00 | ₩2,325.00 | ₩1,630.00 | 652,684 | |
| ₩2,295.00 | -65.00 | -2.8% | ₩2,330.00 | ₩2,450.00 | ₩2,260.00 | 49,243 | |
| ₩2,360.00 | -90.00 | -3.7% | ₩2,495.00 | ₩2,500.00 | ₩2,350.00 | 17,316 | |
| ₩2,450.00 | +10.00 | +0.4% | ₩2,360.00 | ₩2,480.00 | ₩2,360.00 | 11,090 | |
| ₩2,440.00 | +135.00 | +5.9% | ₩2,395.00 | ₩2,450.00 | ₩2,285.00 | 34,208 | |
| ₩2,305.00 | -140.00 | -5.7% | ₩2,260.00 | ₩2,435.00 | ₩2,260.00 | 48,030 | |
| ₩2,445.00 | -55.00 | -2.2% | ₩2,500.00 | ₩2,595.00 | ₩2,445.00 | 25,239 | |
| ₩2,500.00 | -70.00 | -2.7% | ₩2,465.00 | ₩2,565.00 | ₩2,455.00 | 60,430 | |
| ₩2,570.00 | -205.00 | -7.4% | ₩2,655.00 | ₩2,750.00 | ₩2,570.00 | 47,243 | |
| ₩2,775.00 | -110.00 | -3.8% | ₩2,760.00 | ₩2,850.00 | ₩2,700.00 | 60,004 | |
| ₩2,885.00 | +210.00 | +7.9% | ₩2,740.00 | ₩3,190.00 | ₩2,725.00 | 543,057 | |
| ₩2,675.00 | +20.00 | +0.8% | ₩2,780.00 | ₩2,780.00 | ₩2,615.00 | 46,334 | |
| ₩2,655.00 | -115.00 | -4.2% | ₩2,770.00 | ₩2,795.00 | ₩2,650.00 | 57,821 | |
| ₩2,770.00 | +155.00 | +5.9% | ₩2,615.00 | ₩2,825.00 | ₩2,610.00 | 82,226 | |
| ₩2,615.00 | +90.00 | +3.6% | ₩2,580.00 | ₩2,800.00 | ₩2,580.00 | 77,929 | |
| ₩2,525.00 | -170.00 | -6.3% | ₩2,500.00 | ₩2,680.00 | ₩2,500.00 | 60,237 | |
| ₩2,695.00 | -230.00 | -7.9% | ₩2,880.00 | ₩2,880.00 | ₩2,665.00 | 174,630 | |
| ₩2,925.00 | +425.00 | +17.0% | ₩2,500.00 | ₩3,040.00 | ₩2,490.00 | 789,606 | |
| ₩2,500.00 | -295.00 | -10.6% | ₩2,750.00 | ₩2,790.00 | ₩2,495.00 | 76,198 | |
| ₩2,795.00 | -210.00 | -7.0% | ₩2,960.00 | ₩3,195.00 | ₩2,795.00 | 54,132 | |
| ₩3,005.00 | -30.00 | -1.0% | ₩3,005.00 | ₩3,070.00 | ₩2,990.00 | 17,111 | |
| ₩3,035.00 | +30.00 | +1.0% | ₩3,010.00 | ₩3,085.00 | ₩2,955.00 | 16,261 | |
| ₩3,005.00 | -60.00 | -2.0% | ₩3,000.00 | ₩3,140.00 | ₩2,865.00 | 34,641 | |
| ₩3,065.00 | +140.00 | +4.8% | ₩3,100.00 | ₩3,590.00 | ₩3,050.00 | 237,086 | |
| ₩2,925.00 | -175.00 | -5.6% | ₩3,040.00 | ₩3,095.00 | ₩2,920.00 | 17,728 | |
| ₩3,100.00 | +40.00 | +1.3% | ₩3,195.00 | ₩3,505.00 | ₩3,050.00 | 36,663 |
Splits
4 splits since 2016 · KRX:084650 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-5 | Consolidation | |
| 2-for-1 | Split | |
| 3-for-1 | Split | |
| 2-for-1 | Split |
- Ticker
- KRX:084650
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- KRX
- Currency
- KRW
LabGenomics Co., Ltd. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
Valuation
EV/sales 0.0× against a median of 2.0×: the lowest of 11 Diagnostics & research services companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- ₩3.46B KRW
- P/E
- Loss
- EV/sales
- 0.0×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.1×
- Gross margin
- 34.1%
- Operating margin
- −49.8%
- Net margin
- −66.5%
- Debt to equity
- 0.1×
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| LabGenomics Co., Ltd. · KRX:084650 | US$13.28M | US$2.59M | n/a | 0.0× | n/a | 0.1× | −66.5% | 0.1× | n/a |
| Biosynex SA · EURONEXT:ALBIO | US$15.37M | US$73.75M | n/a | 0.7× | 2.3× | 0.4× | −61.1% | 1.9× | n/a |
| Verici DX PLC · LSE:VRCI | US$15.25M | US$13.61M | n/a | 3.6× | n/a | 2.6× | −189.2% | 0.1× | n/a |
| Medicon Hellas · ATHEX:MEDIC | US$14.99M | US$7.66M | 7.7× | 0.4× | 1.9× | 0.7× | 9.8% | 0.0× | n/a |
| Pharmigene, Inc. · TPEX:7595 | US$14.70M | US$29.38M | n/a | 4.8× | n/a | 1.9× | −36.5% | 2.2× | n/a |
| BCAL Diagnostics Limited · ASX:BDX | US$14.64M | US$18.17M | n/a | 150× | n/a | n/a | n/a | n/a | n/a |
| Rhythm Biosciences Limited · ASX:RHY | US$14.05M | US$11.94M | n/a | 211× | n/a | 5.8× | n/a | 0.1× | n/a |
| Noul Co Ltd. · KRX:376930 | US$14.03M | US$6.23M | n/a | 1.6× | n/a | 1.1× | −389.6% | 0.0× | n/a |
| Telescope Innovations Corp · CSE:TELI | US$13.52M | US$12.59M | n/a | 2.5× | n/a | 5.7× | −56.0% | 0.0× | 1.20 |
| IDT Australia Limited · ASX:IDT | US$13.09M | US$18.52M | n/a | 1.4× | n/a | 1.0× | −13.4% | 0.6× | n/a |
| Bionano Genomics, Inc. · NASDAQ:BNGO | US$11.50M | US$9.88M | n/a | 0.3× | n/a | 0.4× | −96.9% | 0.2× | 1.70 |
| Median of the others | US$14.35M | US$13.10M | 7.7× | 2.0× | 2.0× | 1.1× | −58.6% | 0.1× | 1.45 |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Mar 28, 2024 · Before open | −0.5% |
| Q4 2022 | Feb 13, 2023 · Before open | −0.9% |
| Q3 2022 | Nov 14, 2022 | +2.9% |
| Q4 2021 | Feb 6, 2022 · After close | +6.8% |
| Q3 2021 | Nov 1, 2021 · After close | +1.5% |
| Quarter to Jun 30, 2021 | Aug 18, 2021 · Before open | −0.2% |
| Quarter to Mar 31, 2021 | May 17, 2021 · After close | +4.3% |
| Quarter to Dec 31, 2020 | Feb 8, 2021 · After close | +1.6% |
Financials
Annual, in KRW
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 88.2B | 85.9B | 71.1B | 144.8B | 202.4B | 119.5B | 33.2B | 27.5B | 24.8B | 24.1B |
| Cost of revenue | 57.5B | 54.5B | 40.7B | 48.0B | 77.0B | 47.7B | 19.8B | 18.1B | 15.3B | 13.3B |
| Gross profit | 30.6B | 31.4B | 30.4B | 96.8B | 125.4B | 71.7B | 13.4B | 9.44B | 9.46B | 10.8B |
| Research and development | 1.87B | 2.68B | 2.62B | 1.86B | 556.9M | 350.6M | 350.6M | |||
| Selling, general and administrative | 16.6B | 40.8B | 31.6B | 27.4B | 19.4B | 16.0B | 11.4B | 11.3B | 10.3B | 10.2B |
| Operating income | -53.5B | -21.6B | -6.92B | 66.2B | 104.5B | 53.3B | 775.8M | -3.23B | -2.94B | -8.48M |
| Depreciation and amortization | 10.3B | 6.03B | 4.45B | 3.56B | 3.34B | 3.43B | 3.80B | 1.38B | 1.29B | 1.32B |
| EBITDA | -43.2B | -15.6B | -2.47B | 69.8B | 107.8B | 56.7B | 4.58B | -1.85B | -1.65B | 1.31B |
| Interest expense | 5.73B | 5.51B | 4.95B | 574.0M | 208.0M | 223.8M | 0 | 0 | 0 | 0 |
| Income before tax | -60.3B | -26.0B | -7.13B | 63.4B | 109.1B | 51.8B | 1.08B | -3.37B | -4.30B | 139.0M |
| Income tax | 25.3B | 9.06B | 112.9M | 602.1M | -866.5M | -584.5M | ||||
| Net income | -64.4B | -23.8B | -4.67B | 48.4B | 83.9B | 42.8B | 962.4M | -3.97B | -3.44B | 723.5M |
| Earnings per share, basic | -867.11 | -320.53 | -62.96 | 711.90 | 1,258.17 | 1,259.07 | 31.20 | -145.90 | -133.17 | 28.35 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 6.76B | 24.5B | 42.3B | 354.0K | 282.0K | 37.8B | 2.00B | 399.1M | 495.4M | 2.66M |
| Short-term investments | 51.3B | 26.9B | 73.1B | 38.4B | 28.4B | 15.3B | 12.1B | 13.9B | 6.16B | 2.05B |
| Receivables | 11.6B | 38.0B | 37.1B | 35.3B | 68.4B | 31.5B | 18.4B | 16.1B | 14.6B | 11.8B |
| Inventory | 2.78B | 3.74B | 2.27B | 1.74B | 2.69B | 2.46B | 710.1M | 513.7M | 681.3M | 551.4M |
| Current assets | 74.5B | 135.6B | 160.4B | 174.5B | 170.9B | 87.5B | 33.6B | 31.4B | 22.2B | 24.7B |
| Property, plant and equipment | 57.4B | 55.0B | 54.9B | 19.7B | 7.99B | 7.44B | 6.52B | 6.63B | 6.38B | |
| Goodwill | 55.6B | 58.3B | 54.9B | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K |
| Total assets | 230.1B | 295.7B | 313.5B | 250.7B | 204.3B | 109.4B | 49.5B | 47.1B | 39.9B | 43.2B |
| Accounts payable | 10.1B | 9.65B | 9.29B | 6.56B | 11.4B | 8.09B | 4.21B | 3.87B | 3.82B | 3.65B |
| Current liabilities | 60.2B | 76.3B | 65.1B | 19.9B | 40.7B | 25.0B | 10.6B | 8.66B | 8.11B | 7.97B |
| Long-term debt | 13.1B | 0 | 16.0B | 19.2B | 3.20B | 0 | 6.21B | 6.55B | 8.67B | 9.09B |
| Total debt | 4.20B | 9.88B | 9.35B | 11.2B | ||||||
| Total liabilities | 80.5B | 79.3B | 85.3B | 41.3B | 46.6B | 27.8B | 19.1B | 17.0B | 17.5B | 18.2B |
| Shareholders' equity | 149.6B | 216.3B | 227.8B | 209.3B | 157.7B | 81.5B | 30.4B | 30.1B | 22.3B | 25.0B |
| Shares outstanding | 74.2M | 74.2M | 74.2M | 68.0M | 66.6M | 34.0M | 30.8M | 27.2M | 25.8M | 25.5M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -30.5B | -13.0B | 2.42B | 69.9B | 65.4B | 46.4B | 3.19B | 608.0M | -1.06B | 2.54B |
| Capital spending | -1.66B | -4.55B | -5.20B | -38.3B | -13.7B | -699.2M | -560.9M | -2.03B | -4.30B | -4.08B |
| Free cash flow | -32.2B | -17.5B | -9.02B | 30.6B | 51.5B | 44.9B | 2.63B | -1.42B | -5.36B | -1.53B |
| Cash from investing | -3.76B | -116.6B | -53.3B | -26.1B | -8.59B | -85.8M | -10.6B | -8.40B | -5.32B | |
| Cash from financing | -2.23B | 57.6B | 11.4B | -7.19B | -959.8M | -1.49B | 9.93B | 249.5M | 11.1B | |
| Dividends paid | 0 | -3.32B | ||||||||
| Share buybacks | 0 | 22.7B | -6.54B | 331.6M | -481.7M | 8.00B | 906.2M | |||
| Change in cash | -17.7B | -17.8B | -56.2B | 28.0B | 32.7B | 35.8B | 1.60B | -96.3M | -9.21B | 8.37B |
Cap table
Built by 6ix from LabGenomics Co., Ltd.’s releases
- Common shares
- 9,076,740
- Fully diluted
- 9,076,740
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 9,076,740 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 9,076,740 |
Log in to ask 6ix AI your own questions about LabGenomics Co., Ltd.